Merck’s new pulmonary arterial hypertension (PAH) medication has posted another batch of promising clinical trial data, ...

Patients with pulmonary arterial hypertension and cardiovascular comorbidities may benefit from the use of inhaled or oral ...

Investors seemed to panic after the announcement, with a sell-off driving Keros' share price down 73%, reversing strong gains ...

The Mini Nutritional Assessment was viable for assessing nutritional status and predicting mortality outcomes in patients ...

We are focused on chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension (PAH), interstitial lung ...

Living with Pulmonary Arterial Hypertension (PAH) affects not only patients but also the caregivers who support them, facing ...

Keros Therapeutics is a clinical-stage biopharmaceutical company focusing on rare and hematological diseases. Read why I rate KROS stock a Hold now.

Aerosolized vascular endothelial growth factor/stromal cell-derived factor-1α (VEGFNP/SDFNP) led to a lower pulmonary arterial pressure and prevented right ventricular hypertrophy after monocrotaline ...

StockNews.com lowered shares of United Therapeutics (NASDAQ:UTHR – Free Report) from a strong-buy rating to a buy rating in a research note issued to investors on Thursday morning. Other equities ...

Long-term exposure to high levels of air pollution can accelerate the progression of both chronic respiratory diseases and pulmonary hypertension.

MannKind Corporation is focused on inhaled therapies for endocrine and orphan lung diseases. Check out my recommendation for ...

Pulmonary hypertension (PH) is a chronic, life-threatening condition involving high blood pressure in the arteries of the ...